If any future potential returns from Bex, such as royalties, were to be shared with MEDSIR or others through agreements, it would likely have to be announced via a stock exchange release. No such release has been issued, so that is not the case. Release 2.3.26: ”Bexmarilimab is Faron’s wholly owned, investigational immunotherapy”. And if we were already in the royalty phase for solid tumors, it would mean royalties from big pharma. They might not like it during contract negotiations if the rights were already scattered globally.
If a randomized Phase 2 BEXAR trial of that scale—278 patients—were conducted as a multicenter study in Europe instead of at a single site, it could, with good results, qualify for conditional marketing authorization from the EMA. For the FDA, centers in the US are required. MEDSIR also has its reaches there. Regulators look at the quality of the data, not the sponsor.
Before dreaming of further steps, the work must first begin, starting with the dose finding; that phase can probably be conducted in Barcelona alone. We are following the announcements.